For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 22,841 | |||
| General and administrative | 15,761 | |||
| Total operating expenses | 38,602 | |||
| Operating loss | -38,602 | |||
| Interest expense - royalty agreement | -5,818 | |||
| Interest expense - convertible notes payable | 0 | |||
| Fair value adjustments on derivative liabilities - royalty agreement | -394 | |||
| Fair value adjustments on convertible notes payable | 0 | |||
| Fair value adjustments on derivative liabilities - contingent value right liability | -218 | |||
| Other income - german r&d tax credit receivable | 0 | |||
| Interest income, net | 2,590 | |||
| Other income (expense), net | 727 | |||
| Loss before income taxes | -41,715 | |||
| Income tax benefit (expense) | 0 | |||
| Net loss | -41,715 | |||
| Foreign currency translation gain | 80 | |||
| Comprehensive loss | -41,635 | |||
| Basic EPS | -3.71 | |||
| Diluted EPS | -3.71 | |||
| Basic Average Shares | 11,251,250 | |||
| Diluted Average Shares | 11,251,250 | |||
PALVELLA THERAPEUTICS, INC. (PVLA)
PALVELLA THERAPEUTICS, INC. (PVLA)